10x Genomics, Inc. TXG
Set alert
At close · Oct 30
After hours · Oct 30, 7:23 PM ET
- YTD
- +329.86%
- 1 year
- +463.59%
- Open
- 73.65
- Prev close
- 81.55
- Mkt cap
- 9.13B
- Vol
- 5.22M
- Avg vol
- 3.37M
- EPS
- -0.59
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 67.42
- High
- 75.77
- Forward P/E
- 913.53
- Beta
- 1.99
- Short ratio
- 3.09
- Inst. own
- 116.04%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 74.05
- 200-d avg
- 40.33
- 1y target
- 77.50
3M chart
Events in this range
- Aug 6, 2026Earnings: -0.14; estimate -0.24308; surprise 42.41%
- Sep 28, 2026Rating: Piper Sandler · Neutral → Neutral
- Sep 29, 2026Rating: Leerink Partners · Market Perform → Market Perform
- Oct 7, 2026Rating: Barclays · Overweight → Overweight
- Oct 12, 2026Rating: Canaccord Genuity · Buy → Buy
- Oct 13, 2026Rating: Morgan Stanley · Equal-Weight → Equal-Weight
- Oct 13, 2026Rating: TD Cowen · Hold → Hold
Signals (18)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| MACD: Sell Signal | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 28, 2026 | 4 days ago |
| SMA: Bullish | Oct 26, 2026 | 6 days ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 7, 2026 | 3 weeks ago |
| RSI: Overbought | Sep 24, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 14, 2026 | 1 month ago |
| RSI: Overbought | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| RSI: Overbought | Aug 10, 2026 | 2 months ago |
Key statistics
- Market cap
- 9.13B
- Enterprise value
- 10.15B
- Trailing P/E
- 0.00
- Forward P/E
- 913.53
- PEG ratio
- 0.00
- Price / sales
- 14.79
- Price / book
- 11.05
- EPS (TTM)
- -0.59
- Beta
- 1.99
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -12.18%
- Revenue (TTM)
- 616.91M
- Revenue growth
- -12.70%
- Free cash flow
- 179.66M
- Total cash
- 552.03M
- Total debt
- 78.80M
- Return on equity
- -9.40%
- Shares outstanding
- 120.21M
- Short % of float
- 14.33%
- 50-day average
- 74.05
- 200-day average
- 40.33
Analyst view
Consensus: buy
- Target (low)
- 50.00
- Target (mean)
- 77.50
- Target (high)
- 110.00
- Strong buy1
- Buy5
- Hold12
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.02.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.267 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.24308 | -0.14 | +0.10 | +42.41% |
| May 7, 2026 | Mar 31, 2026 | -0.29 | -0.10 | +0.19 | +65.52% |
| Feb 12, 2026 | Dec 31, 2025 | -0.19 | -0.13 | +0.06 | +31.58% |
| Nov 6, 2025 | Sep 30, 2025 | -0.07 | -0.22 | -0.15 | -214.29% |
| Aug 7, 2025 | Jun 30, 2025 | -0.35 | 0.28 | +0.63 | +180.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | TD Cowen | main | Hold | Hold |
| Oct 13, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Oct 12, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 7, 2026 | Barclays | main | Overweight | Overweight |
| Sep 29, 2026 | Leerink Partners | main | Market Perform | Market Perform |
| Sep 28, 2026 | Piper Sandler | main | Neutral | Neutral |
About 10x Genomics, Inc.
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- 10xgenomics.com
News
- 3 Promising Genomics Stocks to Add to Your Portfolio Now
- Vertiv, Evercore, Brinker, GE HealthCare And Other Big Stocks Moving Higher On Wednesday
- 10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference
- TD Cowen Maintains Hold on 10x Genomics, Raises Price Target to $70
- Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $70
- Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $100
- Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
- Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $110
- 10x Genomics Partners With Fred Hutchinson Cancer Center Over Use Of Single Cell, Spatial Technologies In Both Solid Tumor And Hematologic Malignancies
- Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
Your note
Sign in to keep a note on TXG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HINDSON BENJAMIN J | President | Sale | Aug 23, 2026 | 488,182 |
| KOSARAJU SRIDHAR | Director | Stock Award(Grant) | Jun 3, 2026 | 68,278 |
| MATEO ALAN V. | Director | Stock Award(Grant) | Jun 3, 2026 | 85,877 |
| POPOVITS KIMBERLY J | Director | Stock Award(Grant) | Jun 3, 2026 | 37,445 |
| SAXONOV SERGE WILSON | Chief Executive Officer | Sale | Sep 21, 2026 | 1,335,170 |
| STUELPNAGEL JOHN R | Director | Sale | Sep 2, 2026 | 328,436 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.67% | 17,629,266 | 1.23B | Jun 29, 2026 |
| Blackrock Inc. | 8.99% | 10,804,070 | 756.72M | Jun 29, 2026 |
| ARK Investment Management, LLC | 8.32% | 10,003,057 | 700.61M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.81% | 6,982,492 | 489.05M | Jun 29, 2026 |
| Quantinno Capital Management, LP | 4.55% | 5,469,698 | 383.10M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.23% | 5,082,594 | 355.98M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.94% | 3,528,683 | 247.15M | Jun 29, 2026 |
| ARK ETF Trust-ARK Innovation ETF | 2.62% | 3,148,101 | 220.49M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.52% | 3,032,629 | 212.41M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.12% | 2,548,523 | 178.50M | Jun 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 2.08% | 2,498,429 | 174.99M | Sep 29, 2026 |
| Fidelity Select PORT.s-Select Medical Technology and Devices PORT. | 1.99% | 2,392,772 | 167.59M | Aug 30, 2026 |